Plant ID: NPO11713
Plant Latin Name: Hypericum scabrum
Taxonomy Genus: Hypericum
Taxonomy Family: Hypericaceae
NCBI TaxonomyDB:
1137022
Plant-of-the-World-Online:
433837-1
Turkey; Pakistan; Iran; Turkmenistan; Afghanistan; Tajikistan; Uzbekistan; China; Iraq; Kazakhstan; Russia
NPSR1; | |
RECQL; TDP1; GLO1; ALOX12; HSD17B10; NOX4; APEX1; POLB; | |
ACHE; | |
TOP2A; | |
PIM1; MET; AXL; FLT3; CDK1; KDR; IGF1R; AURKB; | |
CA12; CA7; CA4; | |
MMP12; | |
HIF1A; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.051E-07 | 6.469E-04 | CYP1A1, CYP1B1, CYP3A4, NOX4 |
BP | GO:0032502; developmental process | GO:0007568; aging | 8.287E-07 | 9.022E-04 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.227E-06 | 1.272E-03 | CA12, CA4, CA7 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.741E-06 | 1.580E-03 | APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.026E-06 | 1.661E-03 | APEX1, POLB |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.738E-06 | 3.126E-03 | CYP1A1, CYP1B1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.074E-06 | 3.674E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 6.441E-06 | 3.791E-03 | AXL, FLT3, IGF1R, KDR, MET |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 8.309E-06 | 4.208E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
BP | GO:0008152; metabolic process | GO:0072593; reactive oxygen species metabolic process | 1.361E-05 | 6.306E-03 | ALOX12, CYP1A1, CYP1B1, NOX4 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.886E-05 | 7.798E-03 | CA12, CA4, CA7 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.021E-05 | 8.001E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019752; carboxylic acid metabolic process | 2.115E-05 | 8.080E-03 | ALOX12, CYP1A1, CYP1B1, GLO1, HIF1A, HSD17B10, NOX4, PIM1 |
BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 2.262E-05 | 8.491E-03 | AXL, FLT3, HIF1A, POLB |
BP | GO:0009987; cellular process | GO:1902531; regulation of intracellular signal transduction | 2.403E-05 | 8.779E-03 | AURKB, AXL, CDK1, CYP1B1, FLT3, HIF1A, IGF1R, KDR, L3MBTL1, MET, NOX4 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 2.620E-05 | 8.779E-03 | ALOX12, CDK1, FLT3, HIF1A, IGF1R, KDR, MMP12, PIM1 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 2.420E-05 | 8.779E-03 | AURKB, AXL, CDK1, FLT3, IGF1R, KDR, MET, PIM1, RECQL, TOP2A |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 3.029E-05 | 9.301E-03 | CYP1A1, CYP3A4 |
BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 3.238E-05 | 9.301E-03 | AXL, HIF1A, MMP12 |
BP | GO:0009987; cellular process | GO:0007346; regulation of mitotic cell cycle | 3.332E-05 | 9.301E-03 | APEX1, AURKB, CDK1, CYP1A1, L3MBTL1, PIM1, TOP2A |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.330E-05 | 9.301E-03 | CYP1A1, CYP1B1, CYP3A4, NOX4 |
BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 3.409E-05 | 9.396E-03 | ALOX12, HIF1A, IGF1R, KDR, MET, NOX4 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.472E-05 | 9.450E-03 | CA12, CA4, CA7 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.649E-06 | 1.088E-04 | CA12, CA4, CA7 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.609E-05 | 1.521E-03 | CYP1A1, CYP1B1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.743E-04 | 1.905E-03 | KDR, HIF1A, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.109E-04 | 1.829E-03 | FLT3, MET, HIF1A |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.201E-05 | 1.584E-03 | CYP1A1, CYP1B1, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.431E-04 | 1.889E-03 | CYP1A1, CYP1B1, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.021E-04 | 1.905E-03 | CYP1A1, CYP1B1, CYP3A4 |
09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 9.715E-04 | 8.015E-03 | POLB, APEX1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; HIF1A; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
NA: NA | GIST | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; ACHE; HIF1A; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |